0001867096-23-000037.txt : 20230317 0001867096-23-000037.hdr.sgml : 20230317 20230317161022 ACCESSION NUMBER: 0001867096-23-000037 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20230313 ITEM INFORMATION: Changes in Registrant's Certifying Accountant ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230317 DATE AS OF CHANGE: 20230317 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Xeris Biopharma Holdings, Inc. CENTRAL INDEX KEY: 0001867096 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-40880 FILM NUMBER: 23742635 BUSINESS ADDRESS: STREET 1: 180 N. LASALLE STREET, SUITE 1600 CITY: CHICAGO STATE: IL ZIP: 60601 BUSINESS PHONE: 844-445-5704 MAIL ADDRESS: STREET 1: 180 N. LASALLE STREET, SUITE 1600 CITY: CHICAGO STATE: IL ZIP: 60601 8-K 1 xers-20230313.htm 8-K xers-20230313
☐000186709600018670962023-03-132023-03-13


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549


FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 17, 2023 (March 13, 2023)


XERIS BIOPHARMA HOLDINGS, INC.

(Exact name of registrant as specified in its charter)
Delaware001-4088087-1082097
(State or other jurisdiction of
incorporation)		(Commission
File Number)		(I.R.S. Employer
Identification No.)

180 N. LaSalle Street, Suite 1600
Chicago, Illinois 60601
(Address of principal executive offices, including zip code)

(844) 445-5704
(Registrant's telephone number, including area code)

Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, par value $0.0001 per shareXERSThe Nasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐



Item 4.01. Changes in Registrant’s Certifying Accountant.
(a) Dismissal of Independent Registered Public Accounting Firm.
On March 13, 2023, the audit committee (the “Audit Committee”) of the board of directors (the “Board”) of Xeris Biopharma Holdings, Inc. and subsidiaries (the “Company”) approved the dismissal of KPMG LLP ("KPMG") as the Company's independent registered public accounting firm and KPMG was dismissed. KPMG was previously the principal independent accountant for the Company. The audit reports of KPMG on the consolidated financial statements of the Company as of and for the years ended December 31, 2022 and 2021 did not contain any adverse opinion or a disclaimer of opinion, nor were they qualified or modified as to uncertainty, audit scope or accounting principles, except as follows:
KPMG’s report on the consolidated financial statements of the Company as of and for the years ended December 31, 2022 and 2021 contained a paragraph stating that “As discussed in Note 2 to the consolidated financial statements, the Company has changed its method of accounting for leases as of January 1, 2022 due to the adoption of Accounting Standards Update 2016-02, Leases (Topic 842)”.
During the fiscal years ended December 31, 2022 and 2021 and the subsequent interim period through March 13, 2023, there were no (i) disagreements (as that term is described in Item 304(a)(1)(iv) of Regulation S-K and the related instructions) with KPMG on any matter of accounting principles or practices, financial statement disclosure or auditing scope or procedure, which disagreements if not resolved to the satisfaction of KPMG, would have caused KPMG to make reference to the subject matter of the disagreements in connection with its reports on the Company’s consolidated financial statements for such years, or (ii) reportable events (as that term is described in Item 304(a)(1)(v) of Regulation S-K and the related instructions).
The Company provided KPMG with a copy of the disclosures in this Current Report on Form 8-K prior to its filing with the Securities and Exchange Commission (the “Commission”) and requested KPMG furnish it a letter addressed to the Commission stating whether it agrees with the above statements and, if not, stating the respects in which it does not agree. A copy of that letter, dated March 17, 2023, is filed as Exhibit 16.1 to this Current Report on Form 8-K.
(b) Engagement of New Independent Registered Public Accounting Firm.
On March 13, 2023, the Audit Committee of the Board approved the engagement of Ernst & Young LLP (“E&Y”) as its new independent registered public accounting firm to audit the Company's financial statements for the fiscal year ending December 31, 2023.
During the fiscal years ended December 31, 2022 and 2021 and the subsequent interim period through March 13, 2023, neither the Company nor anyone on its behalf consulted with E&Y regarding (i) the application of accounting principles to a specific transaction, either completed or proposed, or the type of audit opinion that might be rendered on the Company's financial statements and neither a written report nor oral advice was provided to the Company that E&Y concluded was an important factor considered by the Company in reaching a decision as to accounting, auditing or financial reporting issues, (ii) any matter that was the subject of a disagreement (as defined in Item 304(a)(1)(iv) of Regulation S-K and the related instructions), or (iii) any reportable event (as described in Item 304(a)(1)(v) of Regulation S-K).

Item 9.01    Financial Statements and Exhibits.
Exhibit NumberDescription
16.1
104Cover Page Interactive Data File (embedded within the Inline XBRL document)





SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: March 17, 2023Xeris Biopharma Holdings, Inc.
By:/s/ Steven M. Pieper
Name: Steven M. Pieper
Title: Chief Financial Officer





 EX-16.1 2 auditorletter.htm EX-16.1 Document
Exhibit 16.1

March 17, 2023
Securities and Exchange Commission
Washington, D.C. 20549
Ladies and Gentlemen:
We were previously principal accountants for Xeris Biopharma Holdings, Inc. and subsidiaries (the “Company”) and, under the date of March 8, 2023, we reported on the consolidated financial statements of the Company as of and for the years ended December 31, 2022 and 2021. On March 13, 2023, we were dismissed.
We have read the Company’s statements included under Item 4.01 of its Form 8-K dated March 17, 2023, and we agree with such statements, except that we are not in a position to agree or disagree with the Company’s statement that the audit committee of the board of directors approved the dismissal and the statements in Item 4.01(b).
Very truly yours,
/s/ KPMG LLP

 EX-101.SCH 3 xers-20230313.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 4 xers-20230313_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 5 xers-20230313_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Entity Address, State or Province Entity Address, State or Province Document Information, Document [Axis] Document Information, Document [Axis] Entity Tax Identification Number Entity Tax Identification Number Document Information [Line Items] Document Information [Line Items] Title of 12(b) Security Title of 12(b) Security Entity File Number Entity File Number Written Communications Written Communications Document Information [Table] Document Information [Table] Entity Emerging Growth Company Entity Emerging Growth Company Soliciting Material Soliciting Material City Area Code City Area Code Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Local Phone Number Local Phone Number Cover [Abstract] Pre-commencement Tender Offer Pre-commencement Tender Offer Amendment Flag Amendment Flag Entity Ex Transition Period Entity Ex Transition Period Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Trading Symbol Trading Symbol Document Period End Date Document Period End Date Document Type Document Type Entity Registrant Name Entity Registrant Name Entity Address, City or Town Entity Address, City or Town Entity Address, Postal Zip Code Entity Address, Postal Zip Code Entity Central Index Key Entity Central Index Key Document [Domain] Document [Domain] Security Exchange Name Security Exchange Name EX-101.PRE 6 xers-20230313_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 7 R1.htm IDEA: XBRL DOCUMENT v3.22.4
Cover
Mar. 13, 2023
Document Information [Line Items]  
Document Type 8-K
Document Period End Date Mar. 13, 2023
Entity Registrant Name XERIS BIOPHARMA HOLDINGS, INC.
Entity Incorporation, State or Country Code DE
Entity File Number 001-40880
Entity Tax Identification Number 87-1082097
Entity Address, Address Line One 180 N. LaSalle Street,
Entity Address, Address Line Two Suite 1600
Entity Address, City or Town Chicago
Entity Address, State or Province IL
Entity Address, Postal Zip Code 60601
City Area Code 844
Local Phone Number 445-5704
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.0001 per share
Trading Symbol XERS
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Entity Ex Transition Period false
Amendment Flag false
Entity Central Index Key 0001867096
XML 8 xers-20230313_htm.xml IDEA: XBRL DOCUMENT 0001867096 2023-03-13 2023-03-13 false 0001867096 8-K 2023-03-13 XERIS BIOPHARMA HOLDINGS, INC. DE 001-40880 87-1082097 180 N. LaSalle Street, Suite 1600 Chicago IL 60601 844 445-5704 false false false false Common Stock, par value $0.0001 per share XERS NASDAQ true false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.4 html 1 24 1 false 0 0 false 0 false false R1.htm 0000001 - Document - Cover Sheet http://xerispharma.com/role/Cover Cover Cover 1 false false All Reports Book All Reports xers-20230313.htm auditorletter.htm xers-20230313.xsd xers-20230313_def.xml xers-20230313_lab.xml xers-20230313_pre.xml http://xbrl.sec.gov/dei/2021 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "xers-20230313.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2021": 24 }, "contextCount": 1, "dts": { "definitionLink": { "local": [ "xers-20230313_def.xml" ] }, "inline": { "local": [ "xers-20230313.htm" ] }, "labelLink": { "local": [ "xers-20230313_lab.xml" ] }, "presentationLink": { "local": [ "xers-20230313_pre.xml" ] }, "schema": { "local": [ "xers-20230313.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd" ] } }, "elementCount": 29, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 24, "memberCustom": 0, "memberStandard": 0, "nsprefix": "xers", "nsuri": "http://xerispharma.com/20230313", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "xers-20230313.htm", "contextRef": "i8e0fdbde45474e3893434b14493992a0_D20230313-20230313", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://xerispharma.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "xers-20230313.htm", "contextRef": "i8e0fdbde45474e3893434b14493992a0_D20230313-20230313", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://xerispharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://xerispharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_DocumentDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Type of the document as assigned by the filer, corresponding to SEC document naming convention standards.", "label": "Document [Domain]", "terseLabel": "Document [Domain]" } } }, "localname": "DocumentDomain", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://xerispharma.com/role/Cover" ], "xbrltype": "domainItemType" }, "dei_DocumentInformationDocumentAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table.", "label": "Document Information, Document [Axis]", "terseLabel": "Document Information, Document [Axis]" } } }, "localname": "DocumentInformationDocumentAxis", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://xerispharma.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Document Information [Line Items]", "terseLabel": "Document Information [Line Items]" } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://xerispharma.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.", "label": "Document Information [Table]", "terseLabel": "Document Information [Table]" } } }, "localname": "DocumentInformationTable", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://xerispharma.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://xerispharma.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://xerispharma.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://xerispharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://xerispharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://xerispharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://xerispharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://xerispharma.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://xerispharma.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://xerispharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://xerispharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://xerispharma.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://xerispharma.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://xerispharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://xerispharma.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://xerispharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://xerispharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://xerispharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://xerispharma.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://xerispharma.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://xerispharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://xerispharma.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://xerispharma.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r7": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 15 0001867096-23-000037-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001867096-23-000037-xbrl.zip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